WO2021125791A1 - C-n 리간드를 갖는 신규 전이금속 전자전달 착체 및 이를 이용한 전기화학적 바이오센서 - Google Patents
C-n 리간드를 갖는 신규 전이금속 전자전달 착체 및 이를 이용한 전기화학적 바이오센서 Download PDFInfo
- Publication number
- WO2021125791A1 WO2021125791A1 PCT/KR2020/018456 KR2020018456W WO2021125791A1 WO 2021125791 A1 WO2021125791 A1 WO 2021125791A1 KR 2020018456 W KR2020018456 W KR 2020018456W WO 2021125791 A1 WO2021125791 A1 WO 2021125791A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- unsubstituted
- transition metal
- formula
- complex
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims abstract description 53
- 229910052723 transition metal Inorganic materials 0.000 title claims abstract description 41
- 150000003624 transition metals Chemical class 0.000 title claims abstract description 41
- 230000027756 respiratory electron transport chain Effects 0.000 title description 8
- 150000002500 ions Chemical class 0.000 claims description 76
- 229910021115 PF 6 Inorganic materials 0.000 claims description 71
- 229910052762 osmium Inorganic materials 0.000 claims description 60
- 238000006243 chemical reaction Methods 0.000 claims description 49
- -1 halide salt Chemical class 0.000 claims description 45
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 34
- 108090000854 Oxidoreductases Proteins 0.000 claims description 29
- 102000004316 Oxidoreductases Human genes 0.000 claims description 29
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 102000004190 Enzymes Human genes 0.000 claims description 23
- 108090000790 Enzymes Proteins 0.000 claims description 23
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 19
- 150000002907 osmium Chemical class 0.000 claims description 18
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- 239000006163 transport media Substances 0.000 claims description 11
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- IEIIMXZFDMTPNA-UHFFFAOYSA-H Cl[Os](Cl)(Cl)(Cl)(Cl)Cl.N Chemical compound Cl[Os](Cl)(Cl)(Cl)(Cl)Cl.N IEIIMXZFDMTPNA-UHFFFAOYSA-H 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 7
- 125000000033 alkoxyamino group Chemical group 0.000 claims description 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000005276 alkyl hydrazino group Chemical group 0.000 claims description 7
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 7
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 7
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims description 7
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 claims description 6
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 claims description 6
- 239000011714 flavin adenine dinucleotide Substances 0.000 claims description 6
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims description 6
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims description 6
- 230000035484 reaction time Effects 0.000 claims description 6
- 230000002194 synthesizing effect Effects 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000000524 functional group Chemical group 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 229910052707 ruthenium Inorganic materials 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 claims description 4
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 4
- 229910052741 iridium Inorganic materials 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 229910052703 rhodium Inorganic materials 0.000 claims description 4
- 108090000371 Esterases Proteins 0.000 claims description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 3
- 239000012472 biological sample Substances 0.000 claims description 3
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims description 3
- 239000000539 dimer Substances 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000004696 coordination complex Chemical class 0.000 claims description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 2
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 claims description 2
- 125000004585 polycyclic heterocycle group Chemical group 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- 150000004820 halides Chemical class 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 117
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 75
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 69
- 239000012153 distilled water Substances 0.000 description 67
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
- 239000011521 glass Substances 0.000 description 59
- 239000002904 solvent Substances 0.000 description 59
- 239000011259 mixed solution Substances 0.000 description 51
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 51
- 239000000047 product Substances 0.000 description 46
- 239000000243 solution Substances 0.000 description 45
- 239000011347 resin Substances 0.000 description 43
- 229920005989 resin Polymers 0.000 description 43
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 42
- 230000015572 biosynthetic process Effects 0.000 description 42
- 230000002829 reductive effect Effects 0.000 description 42
- 238000003786 synthesis reaction Methods 0.000 description 42
- 239000002244 precipitate Substances 0.000 description 39
- 239000000706 filtrate Substances 0.000 description 36
- 239000012467 final product Substances 0.000 description 36
- 238000001914 filtration Methods 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- 238000005292 vacuum distillation Methods 0.000 description 30
- 125000004432 carbon atom Chemical group C* 0.000 description 24
- 238000002484 cyclic voltammetry Methods 0.000 description 24
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 23
- 238000005481 NMR spectroscopy Methods 0.000 description 23
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 22
- 229940126062 Compound A Drugs 0.000 description 21
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 21
- 229910052786 argon Inorganic materials 0.000 description 21
- 239000012300 argon atmosphere Substances 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 21
- 150000001768 cations Chemical class 0.000 description 21
- 229940088598 enzyme Drugs 0.000 description 21
- 239000007789 gas Substances 0.000 description 21
- 239000012047 saturated solution Substances 0.000 description 21
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 20
- 238000004821 distillation Methods 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000008103 glucose Substances 0.000 description 17
- 238000003828 vacuum filtration Methods 0.000 description 16
- 238000004440 column chromatography Methods 0.000 description 15
- 238000011084 recovery Methods 0.000 description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 14
- 229920000642 polymer Polymers 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000033116 oxidation-reduction process Effects 0.000 description 9
- NBPGPQJFYXNFKN-UHFFFAOYSA-N 4-methyl-2-(4-methylpyridin-2-yl)pyridine Chemical compound CC1=CC=NC(C=2N=CC=C(C)C=2)=C1 NBPGPQJFYXNFKN-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 8
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 8
- 229910052709 silver Inorganic materials 0.000 description 8
- 239000004332 silver Substances 0.000 description 8
- 229910021607 Silver chloride Inorganic materials 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 7
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 229920003169 water-soluble polymer Polymers 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000002562 thickening agent Substances 0.000 description 6
- 108010015776 Glucose oxidase Proteins 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000001308 synthesis method Methods 0.000 description 5
- 239000013076 target substance Substances 0.000 description 5
- SMSLWFZHCONMGQ-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)-1,3-thiazole Chemical compound C1=CSC(C=2SC=CN=2)=N1 SMSLWFZHCONMGQ-UHFFFAOYSA-N 0.000 description 4
- 108010025188 Alcohol oxidase Proteins 0.000 description 4
- 0 C=*1C(c2ccccc2)=NC=C1 Chemical compound C=*1C(c2ccccc2)=NC=C1 0.000 description 4
- 108010089254 Cholesterol oxidase Proteins 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 235000019420 glucose oxidase Nutrition 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- ADFYDNFQSBMAMB-UHFFFAOYSA-N (3-pyridin-2-ylphenyl)methanol Chemical compound OCC1=CC=CC(C=2N=CC=CC=2)=C1 ADFYDNFQSBMAMB-UHFFFAOYSA-N 0.000 description 3
- OQJQPIWVCBJVAZ-UHFFFAOYSA-N 1-methyl-2-phenylimidazole Chemical compound CN1C=CN=C1C1=CC=CC=C1 OQJQPIWVCBJVAZ-UHFFFAOYSA-N 0.000 description 3
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 108010015428 Bilirubin oxidase Proteins 0.000 description 3
- SEQHERDIZNZVAM-UHFFFAOYSA-N CN1C(C=CC=C1)=C1N(C=CC=C1)C Chemical compound CN1C(C=CC=C1)=C1N(C=CC=C1)C SEQHERDIZNZVAM-UHFFFAOYSA-N 0.000 description 3
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 3
- 108010055297 Sterol Esterase Proteins 0.000 description 3
- 102000000019 Sterol Esterase Human genes 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- POSRBSJJCMKQNU-UHFFFAOYSA-N 1-methyl-2-phenylbenzimidazole Chemical compound N=1C2=CC=CC=C2N(C)C=1C1=CC=CC=C1 POSRBSJJCMKQNU-UHFFFAOYSA-N 0.000 description 2
- PVNRLJJDLALBGG-UHFFFAOYSA-N 1-prop-2-enylbenzimidazole Chemical compound C1=CC=C2N(CC=C)C=NC2=C1 PVNRLJJDLALBGG-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- UKOHAQRLZCURNZ-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)-4,5-dihydro-1,3-oxazole Chemical compound O1CCN=C1C1=NC=CS1 UKOHAQRLZCURNZ-UHFFFAOYSA-N 0.000 description 2
- LJCNDNBULVLKSG-UHFFFAOYSA-N 2-aminoacetic acid;butane Chemical compound CCCC.CCCC.NCC(O)=O LJCNDNBULVLKSG-UHFFFAOYSA-N 0.000 description 2
- VQGHOUODWALEFC-UHFFFAOYSA-N 2-phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CC=N1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 description 2
- BSQANOCMGSSXIZ-UHFFFAOYSA-N 2-pyridin-2-yl-3H-cyclopenta[e]oxazine Chemical compound C1C=C2C=CC=C2ON1C3=CC=CC=N3 BSQANOCMGSSXIZ-UHFFFAOYSA-N 0.000 description 2
- IMEVSAIFJKKDAP-UHFFFAOYSA-N 4-methoxy-2-(4-methoxypyridin-2-yl)pyridine Chemical compound COC1=CC=NC(C=2N=CC=C(OC)C=2)=C1 IMEVSAIFJKKDAP-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 2
- 229920002491 Diethylaminoethyl-dextran Polymers 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004642 Polyimide Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 239000002041 carbon nanotube Substances 0.000 description 2
- 229910021393 carbon nanotube Inorganic materials 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013077 target material Substances 0.000 description 2
- YFSUTJLHUFNCNZ-UHFFFAOYSA-M 1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane-1-sulfonate Chemical compound [O-]S(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F YFSUTJLHUFNCNZ-UHFFFAOYSA-M 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- QUMXRZNAUFKBAS-UHFFFAOYSA-N 2-(4-methoxyphenyl)pyridine Chemical compound C1=CC(OC)=CC=C1C1=CC=CC=N1 QUMXRZNAUFKBAS-UHFFFAOYSA-N 0.000 description 1
- KJNZQKYSNAQLEO-UHFFFAOYSA-N 2-(4-methylphenyl)pyridine Chemical compound C1=CC(C)=CC=C1C1=CC=CC=N1 KJNZQKYSNAQLEO-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- XBHOUXSGHYZCNH-UHFFFAOYSA-N 2-phenyl-1,3-benzothiazole Chemical compound C1=CC=CC=C1C1=NC2=CC=CC=C2S1 XBHOUXSGHYZCNH-UHFFFAOYSA-N 0.000 description 1
- WYKHSBAVLOPISI-UHFFFAOYSA-N 2-phenyl-1,3-thiazole Chemical compound C1=CSC(C=2C=CC=CC=2)=N1 WYKHSBAVLOPISI-UHFFFAOYSA-N 0.000 description 1
- XSWCYXIBEZMXMM-UHFFFAOYSA-N 2-pyridin-2-yl-1,3-benzothiazole Chemical compound N1=CC=CC=C1C1=NC2=CC=CC=C2S1 XSWCYXIBEZMXMM-UHFFFAOYSA-N 0.000 description 1
- WELSCYIRWKBEBZ-UHFFFAOYSA-N 2-pyridin-2-yl-1,3-benzoxazole Chemical compound N1=CC=CC=C1C1=NC2=CC=CC=C2O1 WELSCYIRWKBEBZ-UHFFFAOYSA-N 0.000 description 1
- RVRASVNRDWXDFX-UHFFFAOYSA-N 2-pyridin-2-yl-3H-cyclopenta[e]thiazine Chemical compound C1C=C2C=CC=C2SN1C3=CC=CC=N3 RVRASVNRDWXDFX-UHFFFAOYSA-N 0.000 description 1
- JAPJNZIIIIQQHJ-UHFFFAOYSA-N 4,5-diazafluorenone Chemical compound C1=CN=C2C3=NC=CC(=O)C3=CC2=C1 JAPJNZIIIIQQHJ-UHFFFAOYSA-N 0.000 description 1
- NMLYGLCBSFKJFI-UHFFFAOYSA-N 4-pyridin-2-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC=CC=N1 NMLYGLCBSFKJFI-UHFFFAOYSA-N 0.000 description 1
- ZFJRGUPGFRAVKA-UHFFFAOYSA-N CCCCC1=CC=CCC1 Chemical compound CCCCC1=CC=CCC1 ZFJRGUPGFRAVKA-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 108700023156 Glutamate dehydrogenases Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical class CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 101710138959 NAD-specific glutamate dehydrogenase Proteins 0.000 description 1
- 229920000557 Nafion® Polymers 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005638 hydrazono group Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- ARRNBPCNZJXHRJ-UHFFFAOYSA-M hydron;tetrabutylazanium;phosphate Chemical compound OP(O)([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC ARRNBPCNZJXHRJ-UHFFFAOYSA-M 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- PFCMCBTZGOMQIN-UHFFFAOYSA-N indeno[1,2-d]pyridazin-1-one Chemical compound C1=CC=C2C3=CN=NC(=O)C3=CC2=C1 PFCMCBTZGOMQIN-UHFFFAOYSA-N 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000004059 quinone derivatives Chemical class 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3275—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction
- G01N27/3277—Sensing specific biomolecules, e.g. nucleic acid strands, based on an electrode surface reaction being a redox reaction, e.g. detection by cyclic voltammetry
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/002—Osmium compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/28—Electrolytic cell components
- G01N27/30—Electrodes, e.g. test electrodes; Half-cells
- G01N27/327—Biochemical electrodes, e.g. electrical or mechanical details for in vitro measurements
- G01N27/3271—Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1468—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1486—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase
- A61B5/14865—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase invasive, e.g. introduced into the body by a catheter or needle or using implanted sensors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
Definitions
- the present invention relates to a novel transition metal electron transport complex having a C-N ligand and an electrochemical biosensor using the same.
- the biosensor using an enzyme is a chemical sensor used to selectively detect and measure chemical substances contained in a sample by using the biological detection function in which an organism sensitively reacts with a specific substance, such as a functional substance of an organism or a microorganism. It was developed for medical measurement applications such as sensors, and research is being actively conducted in other applications in food engineering or environmental measurement fields.
- Periodic measurement of blood sugar is very important in diabetes management, and various blood sugar meters are being manufactured so that blood sugar can be easily measured using a portable measuring instrument.
- the operating principle of such a biosensor is based on an optical method or an electrochemical method, and this electrochemical biosensor can reduce the effect of oxygen unlike a conventional optical method biosensor, It has the advantage that it can be used without a separate pretreatment. Accordingly, various types of electrochemical biosensors with accuracy and precision are widely used.
- the currently commercialized electrochemical blood glucose sensor mainly uses an enzyme electrode, and more specifically, has a structure in which a glucose oxidase is fixed by a chemical or physical method on an electrode capable of converting an electrical signal.
- the electrochemical blood glucose sensor is based on the principle of measuring the concentration of glucose in the analyte by measuring the current generated by transferring electrons generated when glucose in the analyte such as blood is oxidized by an enzyme to the electrode.
- a redox mediator that is, an electron transport mediator, is essential to facilitate this electron transport reaction. Therefore, the type of enzyme used and the characteristics of the electron transfer mediator most greatly influence the characteristics of the electrochemical biosensor for measuring blood sugar.
- the development trend of blood glucose sensor is an enzymatic reaction instead of GOX in which oxygen participates in the enzymatic reaction with glucose in the blood in order to block the measurement value change due to the difference in oxygen partial pressure (pO 2 ) that varies depending on the blood (venous blood, capillary blood, etc.)
- oxygen partial pressure pO 2
- ferricyanide which is sensitive to humidity
- GDH which excludes oxygen
- organic compounds such as quinone derivatives (Phenanthroline quinone, Quineonediimine, etc.) with excellent stability according to temperature and humidity and Ru complex (ruthenium hexamine, etc.) or organometallic compounds such as osmium complexes are being replaced.
- the most commonly used electron transport medium is potassium ferricyanide [K 3 Fe(CN) 6 ], which is useful for all sensors using FAD-GOX, PQQ-GDH or FAD-GDH due to its low price and high responsiveness. Do.
- the sensor using this electron transfer medium is manufactured and stored because measurement errors occur due to interfering substances such as uric acid or gentisic acid present in the blood, and it is easy to deteriorate due to temperature and humidity. It is difficult to accurately detect low-concentration glucose due to changes in the background current after long-term storage.
- Hexaamine ruthenium chloride [Ru(NH 3 ) 6 Cl 3 ] has higher redox stability than ferricyanide, so the biosensor using this electron transfer medium is easy to manufacture and store, and the change in the background current is small even for long-term storage, so it is stable Although this has a high advantage, it has a disadvantage that it is difficult to manufacture a commercially useful sensor because the reactivity does not match for use with FAD-GDH.
- a continuous glucose monitoring (CGM) system is used to continuously monitor blood sugar to manage diseases such as diabetes, and the existing enzyme sensor that collects blood from the fingertip causes considerable pain due to the needle during blood collection. It cannot be used for these CGMs because it limits the frequency of measurement.
- an improved version of the enzyme sensor that can be attached to the body and minimizes invasion has been developed.
- polyvinylpyrrolidone or polyvinyl By fixing with a polymer backbone such as imidazole, it is intended to prevent problems due to loss of electron transport mediators in the human body.
- N-hydroxysuccinimide which is an active ester
- NHS N-hydroxysuccinimide
- Another object of the present invention is to provide an electrochemical biosensor comprising an oxidation-reduction polymer including the transition metal complex.
- Another object of the present invention is to provide an intermediate compound used in the preparation of the transition metal complex.
- Another object of the present invention is to provide a method for preparing the transition metal complex.
- the present invention Provided is a transition metal complex useful as an electron transport medium having a CN ligand having the following chemical structure.
- M may be one selected from the group consisting of Fe, Co, Ru, Os, Rh and Ir;
- ⁇ is an integer from 1 to 3;
- C-N is a bidentate ligand comprising a phenyl ring and a heterocycle having one or more nitrogen atoms;
- the heterocycle having one or more nitrogen atoms is a heterocycle containing one or more nitrogen atoms, preferably 1 to 3 nitrogen atom(s), or together with one or more nitrogen atoms, the group consisting of O and S It may be a heterocyclic ring including 1 or 2 heteroatoms selected from
- the heterocycle may be a mono, di, tri, or multi-heterocycle, and may be a 4-membered to 16-membered, 5-membered to 15-membered, or 5-membered to 14-membered heterocyclic ring, but is not limited thereto.
- N-N is a bidentate ligand which is a heterocycle containing a nitrogen atom
- m is a negative or positive charge representing -1 to -5 or 1 to 5;
- d is an integer from 0 to 2;
- X is a counter ion, preferably a counter ion selected from the group consisting of F, Cl, Br, I and PF 6 .
- the transition metal complex comprising a C-N ligand according to the present invention improves the performance of an electrochemical sensor excellently when used in an electrochemical sensor.
- 1 is a diagram showing that weak osmium-chloride bonds are broken in the case of analysis through ESI-MS.
- FIG. 2 is a view showing the structure of various osmium complexes (hereinafter, also referred to as "C-N complex (C-N complex)”) having a C-N ligand synthesized in the second step of the embodiment.
- C-N complex C-N complex
- 3a-c are diagrams showing the structure of the osmium complex according to the present invention having a C-N ligand and an N-N ligand synthesized in the third step of Examples.
- FIG. 4 is a graph comparing cyclic voltammetry curves showing electrochemical properties of osmium complexes (Os-complexes 13, 14, 15 and 16) according to the present invention.
- FIG. 6 is a cyclic voltammetry curve showing the electrochemical characteristics of the osmium complex (Os-complex 2) according to the present invention.
- FIG. 7 is a cyclic voltammetry curve showing the electrochemical characteristics of the osmium complex (Os-complex 3) according to the present invention.
- FIG. 10 is a cyclic voltammetry curve showing the electrochemical characteristics of the osmium complex (Os-complex 6) according to the present invention.
- FIG. 11 is a cyclic voltammetry curve showing the electrochemical characteristics of the osmium complex (Os-complex 7) according to the present invention.
- FIG. 13 is a cyclic voltammetry curve showing the electrochemical characteristics of the osmium complex (Os-complex 9) according to the present invention.
- 21 is a cyclic voltammetry curve showing the electrochemical characteristics of the osmium complex (Os-complex 17) according to the present invention.
- Os-complex 18 is a cyclic voltammetry curve showing the electrochemical characteristics of the osmium complex (Os-complex 18) according to the present invention.
- Os-complex 19 is a cyclic voltammetry curve showing the electrochemical characteristics of the osmium complex (Os-complex 19) according to the present invention.
- 25 is a cyclic voltammetry curve showing the electrochemical characteristics of the osmium complex (Os-complex 21) according to the present invention.
- halo or “halogen” means, for example, fluoro, chloro, bromo and iodo.
- alkyl refers to an aliphatic hydrocarbon radical, and includes both straight-chain or branched hydrocarbon radicals.
- aliphatic hydrocarbons having 1 to 6 carbon atoms are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl. , isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl and 2-ethylbutyl.
- alkyl means alkyl having 1 to 6 carbon atoms, preferably alkyl having 1 to 4 carbon atoms, more preferably alkyl having 1 to 6 carbon atoms.
- alkoxy refers to an -O-alkyl or an alkyl-O- group, wherein the alkyl group is as defined above. Examples include, but are not limited to, methoxy, ethoxy, n-propoxy, n-butoxy, t-butoxy. Alkoxy groups may be unsubstituted or substituted with one or more suitable groups.
- hydroxy or “hydroxyl”, alone or in combination with other terms, means —OH.
- amino refers to —NH 2 ; “Nitro” represents -NO 2 .
- aryl is derived by removing one hydrogen atom from one carbon atom in the parent aromatic ring system, for example, having 6 to 20 carbon atoms, 6 to 12 carbon atoms, or 6 to 10 carbon atoms. aromatic hydrocarbons.
- the aryl may include bicyclic radicals comprising saturated, partially unsaturated rings and fused aromatic rings.
- Exemplary aryl groups include radicals derived from benzene (phenyl), substituted phenyl, biphenyl, naphthyl, tetrahydronaphthyl, fluorenyl, toluyl, naphthalenyl, anthracenyl, indenyl, indanyl, and the like. may, but is not limited to.
- Aryl groups may be unsubstituted or substituted with one or more suitable groups.
- substitution means that at least one hydrogen atom is a halogen atom (eg, F, Cl, Br, or I), a cyano group, a hydroxyl group, a thiol group, a nitro group, Amino group, imino group, azido group, amidino group, hydrazino group, hydrazono group, oxo group, carbonyl group, carbamyl group, ester group, ether group, carboxyl group or a salt thereof, sulfonic acid group or a salt thereof, phosphoric acid or a salt thereof, an alkyl group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, a haloalkenyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, an alkynyl
- Chemical Formula 1 may be represented by any one of Chemical Formulas 2 to 4 as follows.
- M may be one selected from the group consisting of Fe, Co, Ru, Os, Rh and Ir;
- m is a negative or positive charge representing -1 to -5 or 1 to 5;
- d is an integer from 0 to 2;
- X is a counter ion, preferably a counter ion selected from the group consisting of F, Cl, Br, I and PF 6 .
- M may be Os.
- the C-N ligand may be represented by the structure of Formula 5 below.
- L C is a heterocyclic ring containing at least one nitrogen atom, and is connected to a phenyl ring at the 2nd position of the heterocyclic ring;
- R L is any functional group of the heterocyclic compound Lc
- R 1 is a moiety coordinated with the transition metal.
- N-N ligand may be represented by the structure of Formula 6 below.
- L N1 and L N2 are each independently a heterocyclic ring containing at least one nitrogen atom, and L N1 and L N2 are each connected to each other at the 2nd position of the heterocyclic ring;
- the L N1 and R L of the second species that are connected to the L N2 are connected to each other to form a substituted or unsubstituted polycyclic heterocycle with 3 L L N1 and N2.
- the heterocyclic ring is selected from the group consisting of imidazole, pyridine, pyrimidine, pyrazole, isoxazole, oxazole, thiazole, benzothiazole, benzimidazole, benzoxazole and diazafluorenone. There may be more than one type.
- amino, alkoxyamino, alkylthio, alkenyl, aryl, alkyl and tricyclic heterocyclic rings are substituted, these are -F, -Cl, -Br, -I, -OH, oxo, an alkyl group having 1 to 3 carbon atoms and an alkyl group having 1 to 3 carbon atoms.
- One or more selected from the group consisting of 1 to 3 alkoxy groups, preferably 1 to 3 may be substituted.
- the C-N ligand of Formula 5 may be selected from the following structures.
- N-N ligand of Formula 6 may be selected from the following structures.
- the compound of Formula 1 according to the present invention may be one of the transition metal complexes shown below.
- the present invention provides a method for preparing the compound of Formula 1 above.
- the transition metal of the transition metal complex including the CN ligand according to the present invention is osmium
- it can be prepared through three steps of synthesis through an osmium salt sold commercially as an electron transport medium, specifically, the following steps May include:
- iii) preparing a transition metal complex of Formula 1 by introducing an N-N ligand into the C-N complex prepared in step ii).
- the step i) is a step of synthesizing the compound of Formula 7, which is an osmium dimer capable of binding a CN ligand, and an osmium halide salt having an ammonium counterion (hexachloroosmium ammonium salt. [(NH-- 4 ) 2 OsCl 6 ]) is characterized in that it is used as a starting material.
- osmium starting material when synthesizing an osmium dimer to which benzene is attached as shown in Formula 7, a hydrated osmium salt (OsCl 3 ⁇ xH 2 O, H 2 OsCl 6 ⁇ xH 2 O) or An osmium halide salt (Na 2 OsCl 6 ) whose counter ion is sodium is used, but when the hexachloro osmium ammonium salt according to the present invention is used, it has advantages in terms of supply and price.
- step i) 7 to 10 equivalents of 1.3-cyclohexadiene are used relative to hexachloroosmium ammonium salt.
- the reaction temperature during the reaction is 90 o C to 100 o C, and the reaction time is 48 hours to 72 hours.
- the reaction solvent may be an aqueous ethanol solution, more specifically, an 80% (v/v) aqueous ethanol solution, but is not limited thereto.
- it includes the process of adding the reaction intermediate (H 2 O).
- Step ii) is a step of preparing a CN complex by introducing a CN ligand into the osmium dimer of Formula 7 prepared in step i), wherein 2 to 4 equivalents of the CN ligand is used relative to the osmium dimer of Formula 7.
- the reaction temperature during the reaction is 80 o C to 160 o C, and the reaction time is 6 hours to 48 hours.
- Alcohols are used as the reaction solvent, and the alcohols are not limited thereto, but lower alcohols having 1 to 6 carbon atoms, 1 to 4 carbon atoms, or methanol or ethanol may be used.
- the C-N ligand used in step ii) may be used as long as it has a structure in which a phenyl ring and a heterocyclic ring having nitrogen are connected to each other (phenyl ring-(nitrogen)heterocyclic ring).
- it may be a C-N ligand of Formula 5 above.
- the C-N complex may be one selected from the following compounds, but is not limited thereto.
- Step iii) is a step of finally preparing a transition metal complex of Formula 1 by introducing a NN ligand into the CN complex prepared in step ii).
- the NN ligand may be used in the amount of 2.0 to 2.2 equivalents based on the CN complex.
- the reaction temperature during the reaction is 80 o C, and the reaction time is 3 to 36 hours.
- the reaction solvent may be methanol, but is not limited thereto.
- the NN ligand used in step ii) may be used as long as it has a structure in which heterocyclic rings having nitrogen are connected to each other ((nitrogen) heterocyclic ring-(nitrogen) heterocyclic ring).
- it may be an NN ligand of Formula 6 above.
- a further aspect of the present invention relates to a sensing membrane for an electrochemical biosensor comprising an enzyme capable of redoxing a liquid biological sample and an electron transfer mediator including the transition metal complex.
- the oxidoreductase refers to an enzyme that catalyzes the redox reaction of a living body.
- a target material to be measured for example, a biosensor, refers to an enzyme that reacts with a target material to be measured and reduces.
- the reduced enzyme reacts with the electron transfer mediator, and the target substance is quantified by measuring a signal such as a change in current generated at this time.
- the oxidoreductase usable in the present invention may be at least one selected from the group consisting of various dehydrogenases, oxidases, esterases, etc., depending on the redox or detection target substance, From among the enzymes belonging to the enzyme group, an enzyme having the target substance as a substrate may be selected and used.
- the oxidoreductase is glucose dehydrogenase (glucose dehydrogenase), glutamate dehydrogenase, glucose oxidase (glucose oxidase), cholesterol oxidase (cholesterol oxidase), cholesterol esterase (cholesterol esterase), lock
- glucose dehydrogenase glucose dehydrogenase
- glutamate dehydrogenase glucose oxidase
- glucose oxidase glucose oxidase
- cholesterol oxidase cholesterol esterase
- cholesterol esterase cholesterol esterase
- lock At least one selected from the group consisting of lactate oxidase, ascorbic acid oxidase, alcohol oxidase, alcohol dehydrogenase, bilirubin oxidase, etc. can
- the oxidoreductase may include a cofactor that serves to store the hydrogen taken from the oxidoreductase from the target substance to be measured (eg, the target substance), for example, flavin adenine dinu. It may be at least one selected from the group consisting of cleotatide (flavin adenine dinucleotide, FAD), nicotinamide adenine dinucleotide (NAD), and pyrroloquinoline quinone (PQQ).
- FAD cleotatide
- NAD nicotinamide adenine dinucleotide
- PQQ pyrroloquinoline quinone
- glucose dehydrogenase when measuring the blood glucose concentration, glucose dehydrogenase (GDH) may be used as the oxidoreductase, and the glucose dehydrogenase is a flavin adenine dinucleotide containing FAD as a cofactor-glucose dehydrogenation. It may be an enzyme (flavin adenine dinucleotide-glucose dehydrogenase, FAD-GDH), and/or nicotinamide adenine dinucleotide-glucose dehydrogenase containing FAD-GDH as a cofactor.
- the usable oxidoreductase is FAD-GDH (eg, EC 1.1.99.10, etc.), NAD-GDH (eg, EC 1.1.1.47, etc.), PQQ-GDH (eg, EC1.1.5.2, etc.) , glutamate dehydrogenase (eg, EC 1.4.1.2, etc.), glucose oxidase (eg, EC 1.1.3.4, etc.), cholesterol oxidase (eg, EC 1.1.3.6, etc.), cholesterol esterase (eg, EC 3.1.
- FAD-GDH eg, EC 1.1.99.10, etc.
- NAD-GDH eg, EC 1.1.1.47, etc.
- PQQ-GDH eg, EC1.1.5.2, etc.
- glutamate dehydrogenase eg, EC 1.4.1.2, etc.
- glucose oxidase eg, EC 1.1.3.4, etc.
- lactate oxidase eg, EC 1.1.3.2, etc.
- ascorbic oxidase eg, EC 1.10.3.3, etc.
- alcohol oxidase eg, EC 1.1.3.13, etc.
- alcohol dehydrogenase eg, EC 1.1.3.13, etc.
- bilirubin oxidase eg, EC 1.3.3.5, etc.
- the oxidoreductase is a glucose dehydrogenase capable of maintaining an activity of 70% or more in a buffer solution at 37° C. for one week.
- the sensing membrane according to the present invention may contain 20 to 700 parts by weight of the redox polymer, such as 60 to 700 parts by weight or 30 to 340 parts by weight, based on 100 parts by weight of the oxidoreductase.
- the content of the oxidation-reduction polymer may be appropriately adjusted according to the activity of the oxidoreductase.
- the sensing film according to the present invention may further include carbon nanotubes to increase film performance. Specifically, when carbon nanotubes are used together with a transition metal complex, particularly osmium, the electron transfer rate is increased, so that the performance of the sensing film can be further improved.
- the sensing film according to the present invention may further include a crosslinking agent.
- the sensing membrane according to the present invention contains one or more additives selected from the group consisting of surfactants, water-soluble polymers, quaternary ammonium salts, fatty acids, thickeners, etc. as a dispersant for dissolving reagents, adhesives for preparing reagents, stabilizers for long-term storage, etc. may be additionally included for the role of
- the surfactant may serve to distribute the composition evenly over the electrode when dispensing the composition to be dispensed with a uniform thickness. 1 selected from the group consisting of Triton X-100, sodium dodecyl sulfate, perfluorooctane sulfonate, sodium stearate, etc. as the surfactant More than one species can be used.
- the surfactant is added to 100 parts by weight of the oxidoreductase in order to properly perform the role of dispensing the reagent evenly on the electrode and dispensing the reagent with a uniform thickness when dispensing the reagent. to 25 parts by weight, such as 10 to 25 parts by weight.
- oxidoreductase having an activity of 700 U/mg when used, 10 to 25 parts by weight of a surfactant may be contained based on 100 parts by weight of the oxidoreductase, and when the activity of the oxidoreductase is higher than this, the content of the surfactant can be adjusted lower than this.
- the water-soluble polymer may serve as a polymer support for the reagent composition to assist in stabilizing and dispersing the enzyme.
- the water-soluble polymer include polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), polyperfluoro sulfonate, hydroxyethyl cellulose (HEC), hydroxy At least one selected from the group consisting of propyl cellulose (hydroxypropyl cellulose; HPC), carboxy methyl cellulose (CMC), cellulose acetate, polyamide, and the like may be used.
- the reagent composition according to the present invention contains 10 to 70 parts by weight of the water-soluble polymer based on 100 parts by weight of the oxidoreductase, such as in order to sufficiently and appropriately exert a role of helping the stabilization and dispersing of the oxidoreductase. It may be contained in an amount of 30 to 70 parts by weight. For example, when an oxidoreductase having an activity of 700 U/mg is used, it may contain 30 to 70 parts by weight of a water-soluble polymer based on 100 parts by weight of the oxidoreductase, and when the activity of the oxidoreductase is higher than this, the content of the water-soluble polymer can be adjusted lower than this.
- the water-soluble polymer may have a weight average molecular weight of about 2,500 g/mol to 3,000,000 g/mol, for example, about 5,000 g/mol to 1,000,000 g/mol in order to effectively perform a dynamic that helps stabilize and disperse the support and enzyme. have.
- the thickener serves to firmly attach the reagent to the electrode.
- the thickening agent at least one selected from the group consisting of natrozole, diethylaminoethyl-dextran hydrochloride (DEAE-Dextran hydrochloride), and the like may be used.
- an oxidoreductase having an activity of 700 U/mg it may contain 30 to 90 parts by weight of a thickener based on 100 parts by weight of the oxidoreductase, and when the activity of the oxidoreductase is higher than this, the content of the thickener can be adjusted lower than this.
- the present invention may be a device including such an organic electron transport medium, preferably an implantable device.
- the device may be an electrochemical biosensor, and more preferably an electrochemical glucose (blood sugar) sensor.
- the type of the electrochemical biosensor is not limited, but may preferably be a continuous blood glucose monitoring sensor.
- the present invention provides, for example, an electrode, an insulator, a substrate, a sensing layer including the redox polymer and a redox enzyme, and a diffusion layer ), a protection layer, and the like.
- the electrode two kinds of electrodes such as a working electrode and a counter electrode may be included, and three kinds of electrodes such as a working electrode, a counter electrode and a reference electrode may be included.
- the biosensor according to the present invention includes an oxidation-reduction polymer comprising the organic-based electron transfer mediator of Formula 1 and a liquid biological sample on a substrate having at least two, preferably two or three electrodes.
- It may be an electrochemical biosensor manufactured by applying a reagent composition containing an enzyme capable of oxidation-reduction and then drying.
- a working electrode and a counter electrode are provided on opposite surfaces of a substrate, and a sensing film containing an oxidation-reduction polymer having an organic-based electron transport medium according to the present invention is laminated on the working electrode.
- a planar electrochemical biosensor characterized in that an insulator, a diffusion film and a protective film are sequentially stacked on both sides of a substrate provided with a working electrode and a counter electrode.
- the substrate may be made of one or more materials selected from the group consisting of polyethylene terephthalate (PET), polycarbonate (PC), and polyimide (PI).
- PET polyethylene terephthalate
- PC polycarbonate
- PI polyimide
- the working electrode may use a carbon, gold, platinum, silver or silver/silver chloride electrode.
- a gold, platinum, silver, or silver/silver chloride electrode can be used as the counter electrode, and a three-electrode including a reference electrode can be used.
- a gold, platinum, silver, or silver/silver chloride electrode may be used as a reference electrode, and a carbon electrode may be used as a counter electrode.
- Nafion, cellulose acetate, or silicone rubber may be used as the diffusion film, and silicone rubber, polyurethane, polyurethane-based copolymer, etc. may be used as the protective film, but is not limited thereto.
- silver chloride or silver may be used because the counter electrode serves as a reference electrode, and in the case of three electrodes, silver chloride or silver is used as the reference electrode, and a carbon electrode may be used as the counter electrode.
- the embodiment of the present invention exemplifies a biosensor for measuring glucose as an applicable example of the electrochemical biosensor, cholesterol, lactate, creatinine, hydrogen peroxide, It can be applied to biosensors for quantification of various substances such as alcohol, amino acids, and glutamate.
- Mass spectra were obtained at Sogang University's Organic Chemistry Research Center through ThermoFisher Scientific's ESI-Iontrap mass spectrometer for low resolution and ThermoFisher Scientific's ESI-orbitrap mass spectrometer for high resolution.
- the osmium complex represented by Formula 1 it can be synthesized through three steps from a commercially available osmium halide salt [(NH--4 ) 2 OsCl 6 ].
- the first step is a step of synthesizing an osmium salt in a tetravalent ionic state in the form of an osmium dimer in a divalent ionic state.
- the second step is a step of synthesizing the synthesized osmium dimer into an osmium complex in which the CN ligand, which is the first ligand, is bound.
- the third step is a step of synthesizing the osmium complex represented by Formula 1 by binding the remaining identical NN ligands.
- the proposed synthesis method uses an osmium halide salt [(NH-- 4 ) 2 OsCl 6 ] whose counter ion is ammonium as a starting material, and has an advantage in terms of supply and price compared to osmium starting materials known in the literature. .
- Hexachloroosmium ammonium salt (4.5 g, 10.2 mmol) and 80% aqueous ethanol solution (20 mL) were added to a glass culture tube to make a suspension. Thereafter, 1,3-cyclohexadiene (5.0 mL, 74.2 mmol) was added thereto, followed by stirring at 100° C. for one day. After cooling to room temperature, distilled water (15 mL) was added, followed by stirring for an additional day. After completion of the reaction, the reaction solution was cooled to room temperature, diethyl ether (8 mL) and ethanol (20 mL) were added, and stored at 0° C. for 2 hours to obtain a yellow precipitate.
- the weak osmium-chloride bond is broken and a mass value appears along with a specific mass reformation of the compound exchanged with methanol, a solvent used for mass spectrometry.
- the form of the dimer is broken, benzene remains in the osmium monomer, and the mass reformation and mass value of the compound in which the osmium-chloride bond is exchanged with methanol as the solvent are also shown.
- Compound A thus obtained was used in the second synthesis step without further purification to synthesize an osmium complex, followed by purification and analysis.
- Various osmium complexes having a C-N ligand shown in FIG. 2 were synthesized by the proposed synthesis method.
- CN complex 1 N-methylphenylimidazole was used as the CN ligand. Unlike other complexes, a product was obtained in which a nitrogen moiety of the ligand was attached instead of an osmium-chloride bond.
- the third step is a process of introducing two identical N-N ligands into the osmium complex to which the C-N ligand was introduced in the second step.
- various osmium organometallic complexes corresponding to Chemical Formula 1 as shown in FIGS. 3a-c were synthesized.
- the resulting organometallic complex was synthesized through ESI-MS and the oxidation state of the material was determined. The yield was calculated based on the high oxidation state.
- Cyclic voltammograms were measured using Palmsens' EmStat 3 model for Os-complex 1 to 7 and Os-complex 8, and CHI1040C from CH Instruments for Os-complex 8 and Os-complex 10 to 20. Measured through the model. Ag/AgCl was used as a reference electrode, a carbon glass electrode was used as a working electrode, and a Pt electrode was used as a counter electrode for measurement at a scan rate of 10 mV/s. Substances having a counter ion of PF 6 ⁇ were measured at a concentration of 3 mg/mL in an acetonitrile solution of 0.1M TBAP. Concentrations of substances having a counter ion of Cl ⁇ were measured in a non-constant state. The results are shown in Table 1 and FIGS. 5 to 25 below.
- the resulting precipitate was filtered and washed with distilled water and excess diethyl ether to obtain a final product having a counter ion of PF 6 -.
- the product was dissolved in a small amount ( ⁇ 1 mL) of acetonitrile and stirred in excess distilled water (25 mL) with Dowex 1x4 chloride resin for 24 hours. The resin was removed by vacuum filtration, and the filtrate was dissolved again in distilled water after removing the solvent by vacuum distillation, stirred at 100 o C for 18 hours, and the solvent was removed to obtain a product having a counter ion of Cl -.
- the resulting precipitate was filtered and washed with distilled water and excess diethyl ether to obtain a final product having a counter ion of PF 6 -.
- the product was dissolved in a small amount ( ⁇ 1 mL) of acetonitrile and stirred in excess distilled water (25 mL) with Dowex 1x4 chloride resin for 24 hours. The resin was removed by vacuum filtration, and the filtrate was dissolved again in distilled water after removing the solvent by vacuum distillation, stirred at 100 o C for 18 hours, and the solvent was removed to obtain a product having a counter ion of Cl -.
- the resulting precipitate was filtered and washed with distilled water and excess diethyl ether to obtain a final product having a counter ion of PF 6 -.
- the product was dissolved in a small amount ( ⁇ 1 mL) of acetonitrile and stirred in excess distilled water (25 mL) with Dowex 1x4 chloride resin for 24 hours. The resin was removed by vacuum filtration, and the filtrate was dissolved again in distilled water after removing the solvent by vacuum distillation, stirred at 100 o C for 18 hours, and the solvent was removed to obtain a product having a counter ion of Cl -.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Electrochemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Os-complex | Structure | E1/2 (vs Ag/AgCl)/mV |
1 | PF6
-: 215 Cl-: 15(predicted)b |
|
2 | PF6
-: 145 Cl-: (-) 55(predicted) |
|
3 | PF6
-: 160 Cl-: (-) 75 |
|
4 | PF6
-: 205 Cl-: (-) 20 |
|
5 | PF6
-: 390 Cl-: 160(predicted) |
|
6 | PF6
-: 360 Cl-: 130(predicted) |
|
7 | PF6
-: 165 Cl-: (-) 35(predicted) |
|
8 | PF6
-: 385 Cl-: 185(predicted) |
|
9 | PF6
-: 185 Cl-: (-) 15(predicted) |
|
10 | PF6
-: 72 Cl-: (-)128(predicted) |
|
11 | PF6
-: 115 Cl-: (-) 82 |
|
12 | PF6
-: 214 Cl-: (-) 21 |
|
13 | PF6
-: 269 Cl-: 21 |
|
14 | PF6
-: 160 Cl-: (-) 94 |
|
15 | PF6
-: 3 Cl-: (-) 203 |
|
16 | PF6
-: 311 Cl-: 95 |
|
17 | PF6
-: 310 Cl-: 96 |
|
18 | PF6
-: 195 Cl-: (-) 39 |
|
19 | PF6
-: 349 Cl-: 38 |
|
20 | PF6
-: 343 Cl-: 4 |
|
21 | PF6
-: 225 Cl-: 15 |
Claims (20)
- 하기의 화학 구조식을 갖는 전자 전달매개체로서 유용한 전이금속 착체:[화학식 1][M(C-N)α(N-N)3-α]mdX상기 식에서 M은 Fe, Co, Ru, Os, Rh 및 Ir로 이루어지는 군으로부터 선택되는 하나일 수 있고;α는 1 내지 3의 정수이고;C-N은 페닐환 및 하나 이상의 질소원자를 갖는 헤테로환을 포함하는 바이덴테이트 리간드이고;N-N은 질소 원자를 포함하는 헤테로환인 바이덴테이트 리간드이고;m은 -1 ~ -5 또는 1 ~ 5 를 나타내는 음전하 혹은 양전하이고;d는 0 내지 2의 정수이고;X는 반대이온(counter ion)이다.
- 제1항에 있어서, 상기 M은 Os인 것인, 전이금속 착체.
- 제1항에 있어서, 상기 반대이온은 F, Cl, Br, I 및 PF6로 이루어지는 군에서 선택되는 것인, 전이금속 착체.
- 제1항에 있어서, 상기 C-N 리간드는 하기와 같은 화학식 5의 구조로 나타내어지는 것인, 전이금속 착체:[화학식 5]상기 식에서 LC는 질소원자를 하나 이상 포함한 헤테로환이며, 상기 헤테로환의 2번 위치에서 페닐환과 연결되어 있고;RL은 헤테로 고리 화합물 Lc의 모든 작용기이며;RL, R2, R3, R4, R5은 각각 독립적으로 -H, ―F, ―Cl, ―Br, ―I, ―NO2, ―CN, -C(=O)H, ―CO2H, -SO3H, ―NHNH2, ―SH, ―OH, -NH2, 치환 또는 비치환된 알콕시카보닐, 치환 또는 비치환된 알킬아미노카보닐, 치환 또는 비치환된 다이알킬아미노카보닐, 치환 또는 비치환된 알콕시, 치환 또는 비치환된 알킬아미노, 치환 또는 비치환된 다이알킬아미노, 치환 또는 비치환된 알카닐아미노, 치환 또는 비치환된 치환 또는 비치환된 아릴카복시아미도, 치환 또는 비치환된 하이드라지노, 치환 또는 비치환된 알킬하이드라지노, 치환 또는 비치환된 하이드록시아미노, 치환 또는 비치환된 알콕시아미노, 치환 또는 비치환된 알킬싸이오, 치환 또는 비치환된 알케닐, 치환 또는 비치환된 아릴 및 치환 또는 비치환된 알킬로 이루어지는 군으로부터 선택되는 것일 수 있고;R1은 전이 금속과 배위되는 부분이다.
- 제1항에 있어서, 상기 N-N 리간드는 하기와 같은 화학식 6의 구조로 나타내어지는 것인, 전이금속 착체:[화학식 6]상기 식에서 LN1 및 LN2는 각각 독립적으로 질소원자를 하나 이상 포함한 헤테로환으로 LN1과 LN2는 각각 상기 헤테로환의 2번 위치에서 서로 연결되어 있고;상기, RL은 헤테로환인 LN1 및 LN2의 작용기이며, 각각 -H, ―F, ―Cl, ―Br, ―I, ―NO2, ―CN, -C(=O)H, ―CO2H, -SO3H, ―NHNH2, ―SH, ―OH, -NH2 또는 치환 또는 비치환된 알콕시카보닐, 치환 또는 비치환된 알킬아미노카보닐, 치환 또는 비치환된 다이알킬아미노카보닐, 치환 또는 비치환된 알콕시, 치환 또는 비치환된 알킬아미노, 치환 또는 비치환된 다이알킬아미노, 치환 또는 비치환된 알카닐아미노, 치환 또는 비치환된 아릴카복시아미도, 치환 또는 비치환된 하이드라지노, 치환 또는 비치환된 알킬하이드라지노, 치환 또는 비치환된 하이드록시아미노, 치환 또는 비치환된 알콕시아미노, 치환 또는 비치환된 알킬싸이오, 치환 또는 비치환된 알케닐, 치환 또는 비치환된 아릴, 치환 또는 비치환된 알킬이 될 수 있거나, 또는상기 LN1 및 LN2에 각각 연결되어있는 2종의 RL이 서로 연결되어 LN1 및 LN2과 함께 치환 또는 비치환된 3환의 헤테로환을 형성할 수 있고,이때, 상기 LN1 및 LN2에 각각 연결되어있는 2종의 RL이 서로 연결되어 만들어지는 고리는 5원 내지 7원의 고리일 수 있고, 상기 5원 내지 7원의 고리는 oxo (=O), ―CO2H, -SO3H, ―NHNH2, ―SH, ―OH, -NH2 또는 치환 또는 비치환된 알콕시카보닐, 치환 또는 비치환된 알킬아미노카보닐, 치환 또는 비치환된 다이알킬아미노카보닐, 치환 또는 비치환된 알콕시, 치환 또는 비치환된 알킬아미노, 치환 또는 비치환된 다이알킬아미노, 치환 또는 비치환된 알카닐아미노, 치환 또는 비치환된 아릴카복시아미도, 치환 또는 비치환된 하이드라지노, 치환 또는 비치환된 알킬하이드라지노, 치환 또는 비치환된 하이드록시아미노, 치환 또는 비치환된 알콕시아미노, 치환 또는 비치환된 알킬싸이오, 치환 또는 비치환된 알케닐, 치환 또는 비치환된 아릴, 치환 또는 비치환된 알킬로 치환되거나 비치환될 수 있다.
- 짝이온이 암모늄인 전이금속의 할로젠화염을 이용하여 전이금속의 이합체를 합성하는 단계; 상기 전이금속의 이합체에 C-N 리간드를 도입하여 C-N 복합체를 제조하는 단계; 상기 C-N 복합체에 N-N 리간드를 도입하여 화학식 1의 전이금속 착체를 제조하는 단계를 포함하는 것을 특징으로 하는 제1항에 따른 전이금속 착체의 제조방법.
- i) 짝이온이 암모늄인 전이금속의 할로젠화염으로서 헥사클로로 오스뮴 암모늄염을 1,3-사이클로헥사디엔과 반응시켜 오스뮴 이합체인 화학식 7의 비스[(η6-벤젠)다이클로로다이오스뮴[(η6-bz)OsCl2]2 을 제조하는 단계;ii) 상기 단계 i)에서 제조된 비스[(η6-벤젠)다이클로로다이오스뮴[(η6-bz)OsCl2]2에 C-N 리간드를 도입하여 C-N 복합체를 제조하는 단계; 및iii) 상기 단계 ii)에서 제조된 C-N 복합체에 N-N 리간드를 도입하여 상기 화학식 1의 전이금속 착체를 제조하는 단계,를 포함하는 제1항에 따른 화학식 1의 전이금속 착체의 제조방법:[화학식 7]
- 제11항에 있어서, 단계 i)의 헥사클로로 오스뮴 암모늄염에 대해 1.3-사이클로헥사디엔을 7 내지 10 당량 사용하고, 반응 온도는 90 내지 100℃이고, 반응시간은 48 내지 72 시간인 것인, 전이금속 착체의 제조방법.
- 제11항에 있어서, 상기 C-N 리간드는 화학식 7의 오스뮴 이합체에 대해 2 당량 내지 4 당량 사용하고, 반응 온도는 80 내지 160℃ 이고, 반응시간은 6 내지 48 시간인 것인, 전이금속 착체의 제조방법.
- 제11항에 있어서, 상기 N-N 리간드는 화학식 7의 오스뮴 이합체에 대해 2 당량 내지 2.2 당량 사용하고, 반응 온도는 70 내지 90℃ 이고, 반응시간은 3 내지 36 시간인 것인, 전이금속 착체의 제조방법.
- 제1항 내지 제9항 중 어느 한 항에 따른 전이금속 착체를 전자전달매개체로서 포함하는 장치.
- 제16항에 있어서, 상기 장치는 전기화학적 바이오센서인 것인, 장치.
- 제16항에 있어서, 상기 장치는 삽입가능한 것인 장치.
- 액체성 생체시료를 산화환원시킬 수 있는 효소; 및제1항 내지 제9항 중 어느 한 항의 전이금속 착체를 전자전달매개체로 포함하는 전기화학적 바이오센서용 센싱 막.
- 제19항에 있어서, 상기 효소는탈수소효소 (dehydrogenase), 산화효소 (oxidase), 및 에스테르화효소 (esterase)로 이루어진 군에서 선택된 1종 이상의 산화환원효소; 또는탈수소효소, 산화효소, 및 에스테르화효소로 이루어진 군에서 선택된 1종 이상의 산화환원효소와 플라빈 아데닌 디뉴클레오타티드 (flavin adenine dinucleotide, FAD), 니코틴아미드 아데닌 디뉴클레오티드 (nicotinamide adenine dinucleotide, NAD), 및 피롤로퀴놀린 퀴논 (Pyrroloquinoline quinone, PQQ)로 이루어진 군에서 선택된 1종 이상의 보조인자를 포함하는 것인, 전기화학적 바이오센서용 센싱 막.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080087558.1A CN114867732A (zh) | 2019-12-16 | 2020-12-16 | 具有c-n配体的新型过渡金属电子传输络合物及使用其的电化学生物传感器 |
US17/785,507 US20230125122A1 (en) | 2019-12-16 | 2020-12-16 | Novel transition metal electron transfer complex having c-n ligand and electrochemical bio sensor using same |
EP20901134.5A EP4079740A4 (en) | 2019-12-16 | 2020-12-16 | NEW TRANSITION METAL ELECTRON TRANSFER COMPLEX HAVING C-N LIGAND AND ELECTROCHEMICAL BIOSENSOR USING IT |
JP2022537823A JP7398566B2 (ja) | 2019-12-16 | 2020-12-16 | 遷移金属錯体、電子伝達媒介体として使用される化合物、遷移金属錯体の製造方法、遷移金属錯体を電子伝達媒介体として含む装置、電気化学的バイオセンサ用センシング膜 |
AU2020409909A AU2020409909B2 (en) | 2019-12-16 | 2020-12-16 | Novel transition metal electron transfer complex having C-N ligand and electrochemical bio sensor using same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0168319 | 2019-12-16 | ||
KR20190168319 | 2019-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021125791A1 true WO2021125791A1 (ko) | 2021-06-24 |
Family
ID=76477837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/018456 WO2021125791A1 (ko) | 2019-12-16 | 2020-12-16 | C-n 리간드를 갖는 신규 전이금속 전자전달 착체 및 이를 이용한 전기화학적 바이오센서 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230125122A1 (ko) |
EP (1) | EP4079740A4 (ko) |
JP (1) | JP7398566B2 (ko) |
KR (1) | KR102610156B1 (ko) |
CN (1) | CN114867732A (ko) |
AU (1) | AU2020409909B2 (ko) |
WO (1) | WO2021125791A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11542278B1 (en) | 2020-05-05 | 2023-01-03 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
US11667649B2 (en) | 2020-05-05 | 2023-06-06 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11905280B1 (en) | 2023-10-24 | 2024-02-20 | King Faisal University | 2-(benzo[d]oxazol-2-yl)-N'-(picolinoyloxy)acetimidamide as an antimicrobial compound |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004176072A (ja) * | 2002-11-28 | 2004-06-24 | Aisin Seiki Co Ltd | 金属錯体光増感剤と光電気化学電池 |
KR20160082160A (ko) * | 2014-12-31 | 2016-07-08 | 주식회사 아이센스 | 전기화학적 바이오센서 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4995051B2 (ja) | 2007-11-29 | 2012-08-08 | 株式会社桃屋 | 米類の乳酸発酵食品およびその製造方法 |
EP2275494A4 (en) * | 2008-04-24 | 2011-12-21 | Sharp Kk | PYRIDINE METAL COMPLEX, PHOTO ELECTRODE WITH THE METAL COMPLEX AND COLOR-SENSITIVITY SOLAR CELL WITH THE PHOTO ELECTRODE |
US8563737B2 (en) | 2011-02-23 | 2013-10-22 | Universal Display Corporation | Methods of making bis-tridentate carbene complexes of ruthenium and osmium |
FR2986796A1 (fr) | 2012-02-10 | 2013-08-16 | Almetis | Methodes et compositions pour le traitement du cancer |
US10069090B2 (en) * | 2012-11-20 | 2018-09-04 | Universal Display Corporation | Organic electroluminescent materials and devices |
-
2020
- 2020-12-16 EP EP20901134.5A patent/EP4079740A4/en active Pending
- 2020-12-16 US US17/785,507 patent/US20230125122A1/en active Pending
- 2020-12-16 JP JP2022537823A patent/JP7398566B2/ja active Active
- 2020-12-16 AU AU2020409909A patent/AU2020409909B2/en active Active
- 2020-12-16 WO PCT/KR2020/018456 patent/WO2021125791A1/ko unknown
- 2020-12-16 KR KR1020200176631A patent/KR102610156B1/ko active IP Right Grant
- 2020-12-16 CN CN202080087558.1A patent/CN114867732A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004176072A (ja) * | 2002-11-28 | 2004-06-24 | Aisin Seiki Co Ltd | 金属錯体光増感剤と光電気化学電池 |
KR20160082160A (ko) * | 2014-12-31 | 2016-07-08 | 주식회사 아이센스 | 전기화학적 바이오센서 |
Non-Patent Citations (4)
Title |
---|
ALEXANDER D. RYABOV, VALENTIN S. SOUKHAREV, LARISSA ALEXANDROVA, RONAN LE LAGADEC, MICHEL PFEFFER: "Low-Potential Cyclometalated Osmium(II) Mediators of Glucose Oxidase", INORGANIC CHEMISTRY, AMERICAN CHEMICAL SOCIETY., vol. 42, no. 21, 1 October 2003 (2003-10-01), pages 6598 - 6600, XP055045191, ISSN: 00201669, DOI: 10.1021/ic0346578 * |
RICARDO CERON-CAMACHO, C S, N O, R, H F, H F, 16 / H, /-C, 16 C F, H F, C F, 、 H, H F, C F, H F, H F, C N ;, N A, : "Cyclometalated [Os(C-N)x(N-N)(3-x)]m+ mimetics of tris(2,2'-bipyridine)osmium(II): covering a 2 V potential range by known (x = 0, 1) and new (x = 2, 3) species (C-N = o-2-phenylpyridinato)", CHEMICAL COMMUNICATIONS (CAMBRIDGE, ENGLAND), ENGLAND, 14 March 2011 (2011-03-14), England, pages 2823, XP055252418, [retrieved on 20160223] * |
RYABOV ALEXANDER D., CERÓN-CAMACHO RICARDO, SAAVEDRA-DÍAZ OMAR, DENARDO MATTHEW A., GHOSH ANINDYA, LE LAGADEC RONAN, COLLINS TERRE: "TAML Activator-Based Amperometric Analytical Devices as Alternatives to Peroxidase Biosensors", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 84, no. 21, 6 November 2012 (2012-11-06), US, pages 9096 - 9100, XP055822168, ISSN: 0003-2700, DOI: 10.1021/ac301714r * |
See also references of EP4079740A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11542278B1 (en) | 2020-05-05 | 2023-01-03 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
US11667649B2 (en) | 2020-05-05 | 2023-06-06 | Nuvalent, Inc. | Heteroaromatic macrocyclic ether chemotherapeutic agents |
Also Published As
Publication number | Publication date |
---|---|
JP2023516242A (ja) | 2023-04-19 |
AU2020409909B2 (en) | 2024-03-14 |
US20230125122A1 (en) | 2023-04-27 |
KR102610156B1 (ko) | 2023-12-05 |
CN114867732A (zh) | 2022-08-05 |
EP4079740A1 (en) | 2022-10-26 |
AU2020409909A1 (en) | 2022-07-21 |
KR20210076878A (ko) | 2021-06-24 |
JP7398566B2 (ja) | 2023-12-14 |
EP4079740A4 (en) | 2023-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021125791A1 (ko) | C-n 리간드를 갖는 신규 전이금속 전자전달 착체 및 이를 이용한 전기화학적 바이오센서 | |
WO2009145456A2 (ko) | 헤테로사이클 유도체 | |
WO2012102544A2 (ko) | 신규한 유기염료 및 이의 제조방법 | |
WO2016032120A1 (ko) | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 | |
WO2022216094A1 (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
WO2022225313A1 (ko) | 전이금속 착물 또는 산화-환원 중합체를 포함하는 전기화학적 바이오센서 또는 전기화학적 바이오센서용 센싱 막 | |
WO2010120013A1 (ko) | 신규한 로다민 유도체 및 이를 포함한 차아염소산 검출 센서 | |
WO2021162493A1 (ko) | 단백질 키나아제 분해 유도 화합물 및 이의 용도 | |
WO2020060194A1 (ko) | 폴리알릴글라이시딜에터 기반의 산화-환원 고분자 및 이를 이용한 전기화학적 바이오센서 | |
WO2013105753A1 (en) | Substituted piperidine derivatives and methods for preparing the same | |
WO2022145982A1 (ko) | 테트라덴테이트 질소 공여체 리간드를 포함하는 전이금속 착체 및 이를 포함하는 전기화학적 바이오센서 | |
WO2021133144A1 (ko) | 신규한 유기 전자전달매개체 및 이를 포함하는 장치 | |
WO2022146115A1 (ko) | 펜타플루오로페닐 에스터를 포함하는 고분자 및 이를 포함하는 전기화학적 바이오센서 | |
WO2011049274A1 (en) | Imidazole derivatives and compositions for treating melanoma | |
WO2018021826A1 (ko) | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2010032986A2 (ko) | 신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 | |
WO2012153991A2 (ko) | 스트레커 반응용 촉매를 사용하는 키랄성 α-아미노나이트릴의 제조방법 | |
WO2012157900A2 (ko) | 18f-표지 pet 방사성의약품의 전구체 및 그 제조방법 | |
WO2020050470A1 (ko) | 메로시아닌 화합물, 이의 이성질체를 포함하는 dsrna 검출용 조성물 및 dsrna 발현 분석을 이용한 암 진단을 위한 정보 제공 방법 | |
WO2020036329A1 (ko) | 미토콘드리아 내 nad(p)h 검출을 위한 형광 프로브 및 이를 이용한 검출방법 | |
WO2016163727A9 (ko) | 황화수소 검출용 방사성 프로브 | |
WO2012111995A1 (en) | Oxime derivatives as gpr119 agonists | |
WO2014185561A1 (ko) | 신규한 화합물 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 uch-l1 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2022065949A1 (ko) | 인돌리진 골격체 기반 ph 측정용 형광 화합물 및 이의 용도 | |
WO2015064786A1 (ko) | 생체 분자 표지를 위한 시아닌 염료 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20901134 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022537823 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020409909 Country of ref document: AU Date of ref document: 20201216 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020901134 Country of ref document: EP Effective date: 20220718 |